Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. For more information, go to www.bayer.com

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral anticoagulant (NOAC) and is marketed under the brand name Xarelto®. Xarelto is approved for six indications in Korea, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other NOAC. Also, Xarelto recently has received approval for treatment in CAD or PAD based on results from COMPASS trial.

Advertisement (A4)
Website : www.bayer.co.kr